AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

Company update Earnings report AI-generated analysis

📊 AbbVie trades at a forward P/E of 16.39x compared to Merck's 15.29x, representing a modest premium despite higher recent revenue growth.

💰 AbbVie reported Q2 revenue of $16.99 billion (up 10.2%) and adjusted EPS of $3.65 (up 22.9%).

🧬 Skyrizi and Rinvoq combined generated $8.03 billion in quarterly revenue for AbbVie, driving its immunology growth.

📉 Global Skyrizi net revenue increased 24.4% while Rinvoq grew 24.5% on a reported basis.

💊 Merck's Q2 worldwide sales rose 5% to $16.6 billion, with Keytruda and Keytruda Qlex contributing $8.4 billion.

🚀 Merck's Winrevair revenue surged 75% to $588 million, though it remains a small fraction of total sales compared to Keytruda.

⚠️ AbbVie faces concentration risk as Skyrizi and Rinvoq combined contribute nearly half of its quarterly revenue.

🔮 Merck must build additional revenue to offset potential future pressure on Keytruda as U.S. exclusivity approaches in 2028.

📈 The article concludes AbbVie offers greater visibility into an established commercial transition compared to Merck's uncertain future portfolio expansion.

Bullish Signals
  • AbbVie demonstrated strong second-quarter performance with revenue increasing 10.2% to $16.99 billion and adjusted EPS climbing 22.9% to $3.65.
  • The company's immunology medicines, Skyrizi and Rinvoq, generated approximately $8.03 billion in combined quarterly revenue, representing substantial replacement revenue as Humira sales decline.
  • Global Skyrizi net revenue increased 24.4% on a reported basis while Rinvoq grew 24.5%, indicating successful expansion of its core growth drivers.
Risk Factors
  • The combined contribution of Skyrizi and Rinvoq represents nearly half of AbbVie's quarterly revenue, creating substantial dependence on continued immunology growth.
  • Any meaningful slowdown in the growth of Skyrizi or Rinvoq would challenge the earnings expectations supporting AbbVie's current valuation premium.
Full Analysis
AbbVie Inc. (NYSE: ABBV) and Merck & Co., Inc. (NYSE: MRK) are being compared as healthcare investment options, with AbbVie trading at a modest premium of 16.39x forward earnings versus Merck's 15.29x. The analysis highlights that while both companies face the challenge of sustaining earnings as their blockbuster drugs face competition, they are at different stages of this transition. AbbVie demonstrated strong second-quarter performance with revenue increasing 10.2% to $16.99 billion and adjusted EPS climbing 22.9% to $3.65. This growth is driven by its immunology portfolio, specifically Skyrizi and Rinvoq, which generated approximately $8.03 billion in combined quarterly revenue. These figures represent a significant portion of total sales, indicating that AbbVie is successfully generating replacement revenue as Humira sales decline. Merck reported more moderate growth with worldwide sales increasing 5% to $16.6 billion, led by Keytruda and Keytruda Qlex which generated about $8.4 billion. While Merck shows promising growth in Winrevair (up 75%) and Animal Health, its emerging portfolio is currently small relative to its oncology franchise. The article concludes that AbbVie offers greater visibility into an advancing growth transition, whereas Merck's investment case relies heavily on the future success of its next-generation medicines to offset potential Keytruda competition.